Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31278528 | 1.00 | DRD2 (0.46) | DRD2DRD3AADATADRA1APLAU | |
| SCHEMBL11960179 | 0.82 | DRD2 (0.64) | DRD2DRD3ADRA1APLAU | |
| SCHEMBL11960186 | 0.82 | DRD2 (0.64) | DRD2DRD3ADRA1APLAU | |
| SCHEMBL14591309 | 0.82 | PLAU (0.55) | DRD2DRD3AADATADRA1APLAU | |
| Hydrochloric Acid SCHEMBL28996762 | 0.81 | DRD2 (0.62) | DRD2DRD3ADRA1APLAU | |
| SCHEMBL8689448 | 0.79 | ADRA1A (0.52) | AADATADRA1APLAUACHEFYN | |
| SCHEMBL29605223 | 0.79 | ADRA1A (0.52) | AADATADRA1APLAUACHEFYN | |
| SCHEMBL30864984 | 0.78 | ACHE (0.46) | DRD2AADATACHE | |
| SCHEMBL21447755 | 0.77 | DRD2 (0.47) | DRD2DRD3ADRA1APLAUFYN | |
| SCHEMBL13091093 | 0.75 | ACHE (0.39) | AADATACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | claimed |
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12357590-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12350242-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-08 | — | — | US | disclosed |
| US-12064402-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2024-08-20 | — | — | US | disclosed |
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | disclosed |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Clearmind Medicine Inc. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| CN-114903134-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-08-16 | — | — | CN | disclosed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| CN-1259307-C | Acylated indanyl amines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2006-06-14 | — | — | CN | disclosed |
| CN-1491207-A | Acylated indanyl amines and their use as pharmaceuticals | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
| US-5708018-A | 2-aminoindans as selective dopamine D3 ligands | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | DRD2 62/4885DRD3 131/4885AADAT 508/4885 |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | ADH1A, ADH5, ADH1C | DRD2 456/4885DRD3 431/4885AADAT 11/4885 |
| US-12350242-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD2 62/4885DRD3 131/4885AADAT 508/4885 |
| US-12064402-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD2 62/4885DRD3 131/4885AADAT 508/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | DRD2 456/4885DRD3 431/4885AADAT 11/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | DRD2 2866/4885DRD3 2967/4885AADAT 2891/4885 |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | DRD2 2578/4885DRD3 2599/4885AADAT 2821/4885 |
| US-12357590-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | DRD2 62/4885DRD3 131/4885AADAT 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.